Assessment of carboprost tromethamine for reducing hemorrhage in laparoscopic intramural myomectomy
- Authors:
- Ruitao Zhang
- Huirong Shi
- Fang Ren
- Zhongfu Yuan
View Affiliations
Affiliations: Department of Gynecology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
- Published online on: July 20, 2015 https://doi.org/10.3892/etm.2015.2649
-
Pages:
1171-1174
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the present study was to evaluate the effect of carboprost tromethamine on blood loss during laparoscopic myomectomy (LM) in females. Ninety women, who were scheduled for LM due to symptomatic uterine myomas, were randomly divided into three groups. Twenty‑four women were intramyometrially injected with 12 IU diluted vasopressin (vasopressin group), 30 cases received a deep intramuscular injection of 250 µg carboprost tromethamine 30 min prior to myomectomy (carboprost group), and 36 cases received an intramuscular injection of 250 µg carboprost tromethamine followed by a 20 IU oxytocin intravenous infusion at a rate of 120 mU/min during the procedure (carboprost plus oxytocin group). The procedure time, amount of hemorrhage, postoperative reduction in hemoglobin levels, adverse effects, bowel deflation time and time of postoperative hospital stay were compared. The procedure time, amount of hemorrhage and postoperative reduction in hemoglobin levels were not significantly different between the carboprost group and the vasopressin group (P>0.05). In the carboprost plus oxytocin group, the procedure time, amount of hemorrhage and postoperative reduction in hemoglobin levels were 24.3±2.6 min, 51.1±8.4 ml and 6.9±1.5 g/l, respectively, which were significantly less than those in the vasopressin and carboprost groups (all P<0.05). In the carboprost and carboprost plus oxytocin groups, the incidence of mild uterine contraction pain was significantly higher than in the vasopressin group (χ2=12.913, P=0.002). The incidences of other side‑effects were not significantly different among the three groups. The times for bowel deflation and postoperative hospital stay were marginally increased in both the carboprost and carboprost plus oxytocin groups, compared with the vasopressin group, although no significant differences were found among the three groups (P>0.05). Deep intramuscular injections of carboprost tromethamine prior to performing myomectomy could be an effective approach for reducing blood loss from intramural LM, in particular when combined with oxytocin intravenous infusion.
View References
|
1
|
Kongnyuy EJ and Wiysonge CS: Interventions
to reduce haemorrhage during myomectomy for fibroids. Cochrane
Database Syst Rev. 8:CD0053552014.PubMed/NCBI
|
|
2
|
Rovio PH and Heinonen PK: Transvaginal
myomectomy with screw traction by colpotomy. Arch Gynecol Obst.
273:211–215. 2006. View Article : Google Scholar
|
|
3
|
Fukuda M, Tanaka T, Kamada M, Hayashi A,
Yamashita Y, Terai Y and Ohmichi M: Comparison of the perinatal
outcomes after laparoscopic myomectomy versus abdominal myomectomy.
Gynecol Obstet Invest. 76:203–208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soto E, Flyckt R and Falcone T: Endoscopic
management of uterine fibroids: An update. Minerva Ginecol.
64:507–520. 2012.PubMed/NCBI
|
|
5
|
Trehan N: Laparoscopic myomectomy: Methods
to control bleeding. J Gynecol Endosc Surg. 2:33–35. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang CJ, Lee CL, Yuen LT, Kay N, Han CM
and Soong YK: Oxytocin infusion in laparoscopic myomectomy may
decrease operative blood loss. J Minim Invasive Gynecol.
14:184–188. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shimanuki H, Takeuchi H, Kitade M, Kikuchi
I, Kumakiri J and Kinoshita K: The effect of vasopressin on local
and general circulation during laparoscopic surgery. J Minim
Invasive Gynecol. 13:190–194. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bai J, Sun Q and Zhai H: A comparison of
oxytocin and carboprost tromethamine in the prevention of
postpartum hemorrhage in high-risk patients undergoing cesarean
delivery. Exp Ther Med. 7:46–50. 2014.PubMed/NCBI
|
|
9
|
Matsuoka S, Kikuchi I, Kitade M, Kumakiri
J, Kuroda K, Tokita S, Kuroda M and Takeda S: Strategy for
laparoscopic cervical myomectomy. J Minim Invasive Gynecol.
17:301–305. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao F, Jiao Y, Guo Z, Hou R and Wang M:
Evaluation of loop ligation of larger myoma pseudocapsule combined
with vasopressin on laparoscopic myomectomy. Fertil Steril.
95:762–766. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buttino L Jr and Garite TJ: The use of 15
methyl F2 alpha prostaglandin (Prostin 15 M) for the control of
postpartum hemorrhage. Am J Perinatol. 3:241–243. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abdel-Aleem H, Abol-Oyoun EM, Moustafa SA,
Kamel HS and Abdel-Wahab HA: Carboprost trometamol in the
management of the third stage of labor. Int J Gynaecol Obstet.
42:247–250. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vaid A, Dadhwal V, Mittal S, Deka D, Misra
R, Sharma JB and Vimla N: A randomized controlled trial of
prophylactic sublingual misoprostol versus intramuscular
methyl-ergometrine versus intramuscular 15-methyl PGF2 alpha in
active management of third stage of labor. Arch Gynecol Obstet.
280:893–897. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hauksson A, Akerlund M and Melin P:
Uterine blood flow and myometrial activity at menstruation, and the
action of vasopressin and a synthtic antagonist. Br J Obstet
Gynaecol. 95:898–904. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Caras SD, Soykan I, Beverly V, Lin Z and
McCallum RW: The effect of intravenous vasopressin on gastric
myoelectrical activity in human subjects. Neurogastroenterol Motil.
9:151–156. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bankir L, Bouby N and Ritz E: Vasopressin:
A novel target for the prevention and retardation of kidney
disease? Nat Rev Nephrol. 9:223–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tehseen F, Anwar A and Arfat Y:
Intraumbilical veinous injection oxytocin in the active management
of third stage of labour. J Coll Physicians Surg Pak. 18:551–554.
2008.PubMed/NCBI
|
|
18
|
Ozalp E, Tanir HM and Sener T:
Dinoprostone vaginal insert versis intravenous oxytocin to reduce
postpartum blood loss following vaginal or cesarean delivery. Clin
Exp Obstet Gynecol. 37:53–55. 2010.PubMed/NCBI
|
